Health Catalyst Q2 adjusted EBITDA beats estimates
HCAT•Result drivers
- VITALWARE DIVESTITURE - Co said it completed the Vitalware divestiture and fully repaid its credit facility debt, improving balance sheet flexibility
- RESTRUCTURING COSTS - Co incurred restructuring costs related to workforce reductions and board changes during the qtr
- GOODWILL IMPAIRMENT - Co recognized goodwill impairment in the technology reporting unit as a result of impairment indicators and quantitative tests
Quarterly results and business updates
- US healthcare intelligence firm's Q2 revenue fell 13% yr/yr to $70.5 mln
- Adjusted EBITDA for Q2 beat analyst expectations
- Company completed Vitalware divestiture and fully repaid credit facility debt
Guidance for Q3 2026 and full-year 2026
- Health Catalyst expects Q3 2026 revenue of $55 mln to $56 mln
- Company sees Q3 2026 adjusted EBITDA of $0 to $0.5 mln
- Health Catalyst projects full-year 2026 revenue of $246 mln to $249 mln
- Company expects full-year 2026 adjusted EBITDA of $18 mln to $18.5 mln
